Anti-viral drugs Market Size was valued at USD 66.13 Billion in 2023. The Global Anti-viral drugs industry is projected to grow from USD 69.44 Billion in 2024 to USD 102.59 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.98% during the forecast period (2024 - 2032).
Viruses are a definitive parasite as they get sustenance from the host cell and, furthermore, commandeer and guide its metabolic hardware to orchestrate new infection particles. Infections can live and reproduce just inside have a body. Against viral medications are explicitly used to treat viral contaminations and generally act by hindering their objective infections.
Elements drive the development of Anti-viral drugs market size, for example, ascend in medical services consumption, development of innovative work speculation, the rise of infection perilous sicknesses like bird influenza, solid improvement pipeline and expanding occurrence paces of viral diseases, especially HIV.
Covid-19 Analysis:
The episode of the COVID-19 pandemic for the Anti-viral drugs market has essentially expanded the interest in antiviral medications internationally. The treatment of novel Covid has expanded the interest for a wide range of antiviral medications to deal with the sickness. Remdesivir, favipiravir, oseltamivir, and other mixed prescriptions are exceptionally endorsed for the treatment of COVID-19.
Besides, state-run administrations are expanding financing to drug organizations to foster novel therapeutics against COVID-19. For example, in June 2021, the U.S. government has declared more than USD 3 billion speculations to attach the revelation, advancement, and assembling of antiviral prescriptions for COVID-19 treatment. The rising rate of sickness combined with expanding R&D will build the interest for antiviral medications in the following 2 to 3 years.
The European Union has granted authorization to the anti-Covid-19 drug Molnupiravir. Molnupiravir, which is manufactured by Cipla Limited, was given emergency use authorization by the Drug Controller General of India in December 2021. This is noteworthy because it will be the initial antiviral remedy for mild-moderate COVID-19 in high-risk patients that evolve into severe illness at the UK’s MHRA. In addition, it plans to manufacture and sell Molnupiravir across more than one hundred LICs, including India, under a voluntary non-exclusive license agreement with Merck Sharpe Dohme (MSD).
Who are the nine Antiviral Drug Discovery Centers for Pathogens of Pandemic Concerns funded by $577 million from the National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes? They represent novel interdisciplinary partnerships on out-patient drugs to combat COVID-19 and related viral families likely associated with future pandemics such as filoviruses like Ebola viruses or Marburg virus); picornaviruses like enterovirus and many other cold-causing viruses; Flavivirus such as yellow fever-dengue or Zika infecting viruses; Togavirus, Bunyavirus, Paramyxovirus.
In September 2022, Zenara Pharma introduced generic Paxlovid (Nirmatrelvir and Ritonavir) tablets into the market via its wholly-owned subsidiary based in Hyderabad called Biophore India Pharmaceuticals). When sick with symptoms, they treat moderate-to-mild cases of Covid 19. Zenara Pharma’s press release stated that last month, their company was authorized by the Central Drugs Standard Control Organization (CDSCO). For one course of treatment per patient consisting of twenty tablets of Nirmatrelvir (150ml) and ten tablets of Ritonavir (100mg), each box is priced at a maximum of Rs 5,200.
Anti-viral drugs Market Trends
The worldwide Anti-viral drugs market share is driven by expansion in the rated pace of viral diseases. Furthermore, ascend in R&D exercises and improvement of more up-to-date and progressed details, like immunizations and mixed treatment, are relied upon to push the market development.
But significant expenses engaged with drug advancement and development in the interest of elective medications, for example, naturopathy and homeopathy, limit the Anti-viral drugs market development.
Besides, improvement of an expansive range of anti-toxins and valuable learning experiences in the arising economies of Asia-Pacific and LAMEA districts are relied upon to give various open doors to the market development during the gauge time frame.
The market difficulties of the Anti-viral drugs market incorporate a limited antiviral range, inadequacy against dormant infection, advancement of safe medication freaks and poisonous after-effects.
Also, solid, innovative work pipelines of the key part combined with expanding item dispatches are vital drivers in developing the antiviral therapeutics market. For example, in April 2021, Ativan Therapeutics GmbH has gotten EUR 11.4 million in government financing. The organization will utilize the assets to propel its medication ATR-002, which is right now in Phase II clinical review called RESPIRE. Viral therapeutics is industrially accessible for infections similar to flu, hepatitis C, chickenpox, papilloma, and AIDS.
Furthermore, there is expanding improvement in atomic science, advancing medication advancement and the developing reception of nucleoside and nucleotide analogs as first-line hostile to viral.
In view of the current advancement pipeline in the Anti-viral drugs market, numerous little atom-based enemies of viral medications are expected to get item endorsements, driving the market development to gigantic statures. But, the significant expense of antiviral medication treatment can block the market development in creating locales.
The significant factor of the Anti-viral drugs market share in the development of Influenza Anti-viral Drugs portion is the predominance of flu worldwide and a rising number of medication dispatches combined with a few medications ready to go.
Around the world, the current COVID-19 circumstance has expanded the observation of the flu infection among the populace. Different nations, alongside testing for COVID-19 in the test given by the suggestive patient, are likewise trying for flu infection, which has expanded the finding of the sickness.
What's more, the World Health Organization (WHO) is likewise reassuring nations to proceed with routine flu observation, test tests from flu reconnaissance destinations for flu and SARS-CoV-2 infections where assets are accessible, and report epidemiological and lab data as soon as possible to lay out provincial and worldwide stages.
The expanded conclusion of flu is relied upon to influence the Anti-viral drugs market in a positive manner, as more patients will connect for antiviral treatments in the wake of being analyzed. Generally, the COVID-19 pandemic is expected to emphatically affect the market considered.
North America
Europe
Asia-Pacific
LAMEA
Regional Analysis:
Topographically, the Anti-viral drugs market growth is isolated into the Middle East and Africa, North America, Europe, Asia Pacific, and Latin America. Out of these, North America held USD 13.9 billion Anti-viral drugs marketincome in 2018.
This development of the Anti-viral drugs market is inferable from the presence of different key drug organizations in the U.S. Combined with this, the green sign by the USFDA for the send-off of viable and blockbuster treatments, as well as the rising frequency of HIV in this nation, are set to expand development in North America. Europe is likewise expected to develop amazingly because of the presence of ideal repayment approaches.
The Asia Pacific, then again, is expected to show a high CAGR during the approaching time frame. This development is owing to the regular eruptions of viral infections, in particular, pig influenza, dengue, and Ebola, in the arising economies.
Also, upgraded anti-viral drugs market outlook in nations like Japan and India, as well as a laid-out supply network, are probably going to speed up development around here. In Latin America, the legislatures of Mexico and Brazil are taking industrious drives to oversee viral contaminations. Furthermore, the rising number of nonexclusive drug organizations present in this area would add to the development.
Competitive Intensity Within the Industry:
The key part of the Anti-viral drugs market is embracing natural as well as inorganic systems to make due and extend on the lookout. Besides, the central members are zeroing in on expanding United States Food and Drug Administration (FDA) endorsements and item dispatches to use current and future market valuable open doors.
Recent Market Developments:
In January 2022, Lupin sent off the anti-viral drugs market trends in India under the brand name Molnulup for the treatment of COVID-19 grown-ups in the country.
In January 2022, ENTOD Pharmaceuticals sent off MOLENTOD in India. The item will be accessible to retail, scientific experts, drug store chains, medical clinics and online stores at a reasonable cost.
Report Overview:
The report for Global Anti-viral drugs market value of Market Research Future includes a broad essential examination alongside the detailed investigation of subjective as well as quantitative viewpoints by different industry specialists, key assessment pioneers to acquire a more profound knowledge of the market and industry execution.
The Anti-viral drugs market report gives the unmistakable image of the current market situation, which incorporates chronicled and projected market size as far as worth and volume, mechanical headway, large scale affordable and overseeing factors on the lookout.
The report gives detailed data and procedures of the top central participants in the business. The report likewise gives an expansive investigation of the various business sectors' portions and locales. This report is also required:
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â 2032: USD 102.59 billion |
| Â Â CAGR | Â Â 2024-2032: 5.98% |
| Â Â Base Year | Â Â 2019 |
| Â Â Forecast Period | Â Â 2032 |
| Â Â Historical Data | Â Â 2018 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Application, Mechanism of action |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Abbott Laboratories, Novartis International AG, Astra Zeneca AB, Cipla Inc. |
| Â Â Key Market Opportunities | Â Â New product developments |
|   Key Market Drivers | · Rise In Healthcare Expenditure· Growing Research And Development Investment· Emergence Of Virus Life-Threatening Diseases |
Anti Viral Drugs Market Highlights:
Frequently Asked Questions (FAQ) :
market is projected grow at approximately 5.98% CAGR during the assessment period (2024-2032). Anti-viral drugs
The valuation of the global anti-viral drugs market is estimated to increase to USD 102.59 Bn by the end of 2032.
Rising prevalence of life-threatening virus diseases, rise in healthcare expenditure, and growing research and development investment are major drivers of the global anti-viral drugs market.
North America holds the largest share in the global anti-viral drugs market, followed by Europe and the Asia Pacific, respectively.
Merck & Co. Inc., Johnson & Johnson, Gilead Sciences Inc., GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Abbott Laboratories, AstraZeneca AB, Cipla Inc., and Novartis International AG, are some of the major players operating in the anti-viral drugs market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
